| Field | Specification |
|---|---|
| Target | |
| Alternative names | 17-beta-hydroxysteroid dehydrogenase type 2; 17-beta-HSD 2; 20 alpha-hydroxysteroid dehydrogenase; 20-alpha-HSD; E2DH; Estradiol 17-beta-dehydrogenase 2; Microsomal 17-beta-hydroxysteroid dehydrogenase; Short chain dehydrogenase/reductase family 9C member 2; Testosterone 17-beta-dehydrogenase; HSD17B2; EDH17B2; SDR9C2 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human HSD17B2 recombinant protein (Position: Q75-R365). Human HSD17B2 shares 63.6% and 65.2% amino acid (aa) sequence identity with mouse and rat HSD17B2, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes 17-beta-hydroxysteroid dehydrogenase type 2 (gene HSD17B2) in human and mouse samples and is validated for Western blot, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 42.8 kDa, and the supplier reports an observed band at about 37 kDa.
17β-hydroxysteroid dehydrogenase type 2 (HSD17B2) uses NAD+ to oxidize potent sex steroids such as estradiol, testosterone and dihydrotestosterone into their weaker 17-keto forms. By inactivating these hormones in tissues such as placenta, endometrium and liver, it limits local steroid action.
| Target | 17-beta-hydroxysteroid dehydrogenase type 2 (gene HSD17B2; UniProt P37059, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / IgG |
| Reactivity | Human, Mouse |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 42.8 kDa |
| Observed MW | 37 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse) |
|---|---|
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human MCF-7 cells, human RT4 cells, human HepG2 cells, human placenta tissue, mouse liver tissue tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (ICC/IF): A431 cells.
Samples with a confirmed signal (flow cytometry): MCF-7 cells.
Immunogen
Recombinant human HSD17B2 fragment (Gln75–Arg365), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 63.6% and 65.2%, respectively.
Reactivity Notes
The supplier lists reactivity with human and mouse. UniProt places 17-beta-hydroxysteroid dehydrogenase type 2 in the endoplasmic reticulum membrane. Tissue expression noted by UniProt (human): Expressed in placenta. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
